How do I buy shares of IBT?
Shares of IBT and other Canadian stocks can be purchased through an online brokerage account.
What is the target price for Independent Bank Group Inc (IbTX)?
IBTX: Raising target price to $82.00 INDEPENDENT BANK GROUP INC has an Investment Rating of BUY; a target price of $82.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
What is the target price for iRobot Corp (IRBT)?
IRBT: Lowering target price to $69.00 IROBOT CORP has an Investment Rating of HOLD; a target price of $69.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
What is the PE (price/earnings) ratio of international biotechnology Trust (IBT)?
The P/E ratio of International Biotechnology Trust is 3.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 14.10.
How has IBEX Technologies' stock performed in 2022?
IBEX Technologies' stock was trading at C$0.51 at the start of the year. Since then, IBT shares have decreased by 6.9% and is now trading at C$0.48...
When is IBEX Technologies' next earnings date?
IBEX Technologies is scheduled to release its next quarterly earnings announcement on Thursday, June 16th 2022. View our earnings forecast for IBE...
How were IBEX Technologies' earnings last quarter?
IBEX Technologies Inc. (CVE:IBT) released its quarterly earnings results on Thursday, March, 17th. The company reported $0.02 EPS for the quarter....
Who are IBEX Technologies' key executives?
IBEX Technologies' management team includes the following people: Mr. Paul Baehr , Pres, CEO & Chairman (Age 79, Pay $339.4k) Belinda Franco C.A...
Who are some of IBEX Technologies' key competitors?
Some companies that are related to IBEX Technologies include Small Pharma (DMT) , SkinBioTherapeutics (SBTX) , Sirona Biochem (SBM) , Antibe Th...
What other stocks do shareholders of IBEX Technologies own?
Based on aggregate information from My MarketBeat watchlists, some companies that other IBEX Technologies investors own include Aurora Cannabis (A...
What is IBEX Technologies' stock symbol?
IBEX Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IBT."
How do I buy shares of IBEX Technologies?
Shares of IBT and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian...
What is IBEX Technologies' stock price today?
One share of IBT stock can currently be purchased for approximately C$0.48.
Is International Biotechnology Trust a buy right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for International Biotechnology Trust in the last year. There are cur...
How often does International Biotechnology Trust pay dividends? What is the dividend yield for International Biotechnology Trust?
International Biotechnology Trust declared a dividend on Wednesday, December 8th. Shareholders of record on Thursday, December 30th will be paid a...
Is International Biotechnology Trust a good dividend stock?
International Biotechnology Trust pays an annual dividend of GBX 0.28 per share and currently has a dividend yield of 5.02%. IBT has a dividend yie...
What price target forecast have analysts set for IBT?
1 brokerages have issued 1 year price targets for International Biotechnology Trust's stock. Their forecasts range from GBX 260 to GBX 260. On aver...
Who are International Biotechnology Trust's key executives?
International Biotechnology Trust's management team includes the following people: Ms. Lucy Costa Duarte , Head of Investor Relations Ms. Catheri...
Who are some of International Biotechnology Trust's key competitors?
Some companies that are related to International Biotechnology Trust include Fiera Capital (FSZ) , Law Debenture (LWDB) , GCP Infrastructure Inv...
What other stocks do shareholders of International Biotechnology Trust own?
Based on aggregate information from My MarketBeat watchlists, some companies that other International Biotechnology Trust investors own include Ox...
What is International Biotechnology Trust's stock symbol?
International Biotechnology Trust trades on the London Stock Exchange (LON) under the ticker symbol "IBT."
How do I buy shares of International Biotechnology Trust?
Shares of IBT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Som...
What is the patent for IBP-9414?
What is the drug candidate for IBP-9414?
Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications for the invention are currently pending in additional important future markets including the US and Europe. This patent further increases the existing protection of IBTs drug candidate IBP-9414 for which both Orphan Drug Exclusivity and biological data protection have been granted in the USA and EU. The Japanese patent expires in 2036 and the IBP-9414 product covered by this patent is intended to be marketed in Japan after future marketing authorization. “We are very pleased to strengthen and extend our intellectual property protection for the IBP-9414 product through the approved patent in Japan” says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therapeutics ABInfant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available. Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). For additional information please contact Staffan Strömberg, CEODaniel Mackey, CFOInfant Bacterial Therapeutics ABBryggargatan 10111 21 StockholmPhone: +46 70 670 [email protected] Publication This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 20:00 CET on February 9, 2021. Attachment PR 20210209 JP ENG
What is the IBP-9414 study?
IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk.
How many premature infants were recruited for IBP-9414?
Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development program with our drug candidate IBP-9414 , which contains Lactobacillus reuteri as the active substance. The active substance is a naturally occurring bacterial strain found in women's breast milk. The goal of our development is to offer physicians a unique treatment option which is partly intended to prevent very serious medical complications, suc
Where is IBT located?
Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important milestone after recruiting 600 premature infants in the ongoing Clinical Phase III study of IBP-9414. According to the study protocol, a safety and futility analysis will now be performed during which the recruitment will continue. On September 22nd the company announced the reopening of stratum A (weights 500 to 749 grams) after the independent Data Monitoring Committee (DMC) completed an additional sa
What is fair value in accounting?
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm.
When is the next annual meeting of infant bacterial therapeutics?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
IBEX Technologies Inc.'s (CVE:IBT) Stock Is Going Strong: Have Financials A Role To Play?
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, May 4, 2021.
IBEX Announces Results of Annual Meeting
IBEX Technologies (CVE:IBT) has had a great run on the share market with its stock up by a significant 48% over the...
IBEX to Livestream Annual Meeting on February 16
MONTREAL, Feb. 17, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) is pleased to announce that all six nominees listed in its management proxy circular dated January 4, 2022 were re-elected as directors at the Company’s annual and special meeting held today in Montreal.
What is Marketbeat community ratings?
MONTRÉAL, Jan. 21, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) announces that the time of its annual and special meeting of shareholders (the “Meeting”) to be held on Wednesday, February 16, 2022 has been changed to 11 a.m. (eastern time).
What is International Biotechnology Trust?
MarketBeat's community ratings are surveys of what our community members think about International Biotechnology Trust and other stocks. Vote “Outperform” if you believe IBT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is the ticker symbol for IBT?
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of these companies to strategic buyers including major pharmaceutical companies or, in some cases, and through a flotation.
How much is IBTX net income?
International Biotechnology Trust trades on the London Stock Exchange (LON) under the ticker symbol "IBT."
What is fair value in accounting?
Independent Bank Group, Inc. (NASDAQ: IBTX), the holding company for Independent Bank, today announced net income of $60.0 million, or $1.39 per diluted share, for the quarter ended March 31, 2021, compared to $44.2 million, or $1.03 per diluted share, for the quarter ended March 31, 2020 and $58.3 million, or $1.35 per diluted share, for the quarter ended December 31, 2020.
When is the IBTX earnings call 2021?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
When will independent bank pay dividends in 2021?
NEW YORK, NY / ACCESSWIRE / April 27, 2021 / Independent Bank Group, Inc. (NASDAQ:IBTX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 27, 2021 at 8:30 AM Eastern Time.
What is the name of the company that makes the Bona floor cleaner?
The dividend will be payable on November 24, 2021 to stockholders of record as of the close of business on November 11, 2021. The dividend is an increase of $0.02, or 5.9%, from the previous quarterly dividend of $0.34 per share.
What is iRobot Select?
iRobot Corp. (NASDAQ: IRBT), a leader in consumer robots, and Bona, a leading global supplier of premium floor cleaning solutions, today announced an exclusive partnership to provide customers with Bona® Hardwood Floor Cleaner and Bona® Hard-Surface Cleaner solutions, and the Bona® PowerPlus® Microfiber Deep Cleaning Pad that are custom designed and certified for the iRobot Braava® jet m6 robot mop. The co-branded cleaning solutions and microfiber pads will be sold at select retailers in the U.S
What are some examples of robotics companies?
(NASDAQ: IRBT), a leader in consumer robots, today announced the company is expanding its subscription-based iRobot Select membership program to include the recently announced Roomba® j7+ robot vacuum with Clean Base Automatic Dirt Disposal, along with benefits that provide customers with an entirely new and personalized ownership experience.
What is fair value in accounting?
Examples of companies that offer robotics solutions and products include Cognex Corp. (CGNX), Cadence Design Systems Inc. (CDNS), and U.K.-based Blue Prism Group PLC (PRSM). Robot and automation stocks, as represented by the ROBO Global Robotics and Automation Index ETF (ROBO), have outperformed the broader market.
When will iRobot release its second quarter results?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Who led the Series E round of Salsify?
(NASDAQ: IRBT), a leader in consumer robots, announced today it will issue its second-quarter 2021 financial results after market close on Wedneday, July 28, 2021. The earnings press release will be posted at https://investor.irobot.com/news-releases. #N#.
